Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Irpagratinib (ABSK011) is an orally active fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with specificity for FGFR4, exhibiting an IC50 of less than 10 nM. It effectively inhibits FGFR4 auto-phosphorylation and disrupts subsequent signal transduction to downstream pathways. Demonstrating high exposure in pharmacokinetic studies in mice, rats, and dogs, Irpagratinib also displays antineoplastic activity in subcutaneous xenograft tumor models [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry | |
50 mg | Inquiry | Inquiry |
Description | Irpagratinib (ABSK011) is an orally active fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor with specificity for FGFR4, exhibiting an IC50 of less than 10 nM. It effectively inhibits FGFR4 auto-phosphorylation and disrupts subsequent signal transduction to downstream pathways. Demonstrating high exposure in pharmacokinetic studies in mice, rats, and dogs, Irpagratinib also displays antineoplastic activity in subcutaneous xenograft tumor models [1]. |
Synonyms | ABSK011 |
Molecular Weight | 570.59 |
Formula | C28H32F2N6O5 |
CAS No. | 2230974-62-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Irpagratinib 2230974-62-4 Angiogenesis Tyrosine Kinase/Adaptors FGFR ABSK011 inhibitor inhibit